# Ayala Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ayala-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Wilmington, US
- Website: www.ayalapharma.com
- Total disclosed funding: $47M
- Latest round: Series B (May 28, 2019)
- Investors on record: 5

## About

Ayala Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative therapies for various cancers, leveraging targeted approaches to improve patient outcomes in oncology treatment.Founded in 2017, Ayala Pharmaceuticals, Inc. is based in Wilmington, US, and specializes in the development of cancer therapies. The company has undergone strategic adaptations, including its recent merger with Advaxis, Inc. in October 2022 and a planned merger with BioSight Ltd. in late Q3 2023. Ayala has completed a total of six investment deals with its most recent funding round being an IPO in May 2020, where it raised USD 55 mn. Roni Mamluk serves as CEO, overseeing the company’s strategic direction.Ayala Pharmaceuticals, Inc. specializes in developing innovative therapies aimed at treating various forms of cancer, focusing on products such as AL102 and AL101. These therapies target specific pathways involved in tumor growth, selectively inhibiting tumor cell proliferation while minimizing effects on healthy cells. Their therapeutics are designed for cancers with specific genetic mutations and are marketed to a diverse client base including healthcare providers, hospitals, and oncology specialists globally.In the most recent year of 2022, Ayala Pharmaceuticals reported a revenue of USD 692,000 with an EBITDA of USD -37,341,000. The company generates revenue through strategic partnerships and collaborations, primarily focusing on the commercialization of their flagship products AL102 and AL101 in B2B transactions, with direct sales to hospitals and potential royalties from licensing agreements.Ayala Pharmaceuticals plans to utilize recent funding to support the development and commercialization of its therapies. Following the upcoming merger with BioSight Ltd., the company aims to enhance its product portfolio and expand its market reach. The recent merger with Advaxis, Inc. has positioned Ayala for broader market opportunities, and the company is focused on launching new products in the oncology sector. Specific expansion into new markets, particularly in North America, Europe, and Asia, will be targeted as part of their growth strategy.

## Funding rounds

- Series B, May 28, 2019, $30M — Harel Insurance Investments, Novartis, Israel Biotech Fund, aMoon, SBI JI Innovation Advisory
- Series A, Apr 10, 2018, $17M — Harel Insurance Investments, Israel Biotech Fund, aMoon

## Investors

- Harel Insurance Investments — Series A, Series B
- Israel Biotech Fund (https://capitalatlas.ai/funds/israel-biotech-fund) — Series A, Series B
- aMoon (https://capitalatlas.ai/funds/amoon) — Series A, Series B
- Novartis — Series B
- SBI JI Innovation Advisory (https://capitalatlas.ai/funds/sbi-ji-innovation-advisory) — Series B